Evotec SE ADR (EVO)

Name: Evotec SE ADR (EVO) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Evotec SE ADR (EVO)

Stock Card

$1.91

$-0.06 (-3.05%)

As on 28-Aug-2026 16:00EDT

Market cap

$679 Mln

Revenue (TTM)

$722 Mln

P/E Ratio

P/B Ratio

0.9

Div. Yield

0 %

Evotec SE ADR (EVO) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.91 High: 1.95

52 Week Range

Low: 1.87 High: 4.27

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.3 %
ROCE

-- %
Industry P/E

37.32
EV/EBITDA

34.4
Debt to Equity

0
Book Value

$2.2
EPS

$-0.5
Face value

--
Shares outstanding

355,389,118

10 Years Aggregate

CFO

€692.51 Mln

EBITDA

€626.20 Mln

Net Profit

€145.79 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Evotec SE ADR (EVO)	-38.0	-0.5	-33.4	-45.3	-44.7	-40.2	-2.5
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023
Evotec SE ADR (EVO)	-26.0	-64.2	45.0
S&P Small-Cap 600	4.0	7.0	13.9
BSE Sensex	9.1	8.1	18.7

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Evotec SE ADR (EVO)

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing... pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. Read more

Interim CEO, Member of the Management Board & Member of the Supervisory Board

Dr. Mario Polywka DPHIL, Ph.D.
Interim CEO, Member of the Management Board & Member of the Supervisory Board

Dr. Mario Polywka DPHIL, Ph.D.
Headquarters

Hamburg
Website

https://www.evotec.com

FAQs for Evotec SE ADR (EVO)

What is the current share price of Evotec SE ADR (EVO) Today?

The share price of Evotec SE ADR (EVO) is $1.91 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Evotec SE ADR (EVO) has given a return of -44.74% in the last 3 years.

What is the current PB & PE ratio of Evotec SE ADR (EVO)?

Since, TTM earnings of Evotec SE ADR (EVO) is negative, P/E ratio is not available.
The P/B ratio of Evotec SE ADR (EVO) is 0.90 times as on 28-Aug-2026, a 88 discount to its peers’ median range of 7.75 times.

PE & PB ratio at the end of financial year.